NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) — Main securities law firm Bleichmar Fonti & Auld LLP proclaims that a class action lawsuit has been filed in opposition to ADMA Biologics, Inc. (NASDAQ:ADMA) and definite of the Firm’s senior executives for securities fraud after its important stock descend which means of doable violations of the federal securities felony pointers.
Whereas you invested in ADMA Biologics, you are impressed to develop extra files by visiting: https://www.bfalaw.com/circumstances/adma-biologics-class-action-lawsuit.
Key Puny print of the ADMA ($ADMA) Class Motion:
- Lead Plaintiff Slit-off date: August 10, 2026
- Alleged Misconduct: Securities fraud referring to to allegations that ADMA’s reported 20% growth for 2025 changed into as soon as pushed by a channel stuffing diagram
- Supreme Stock Topple: March 24, 2026 – 16.6% Stock Topple
- Court: U.S. District Court for the District of Current Jersey
-
Motion: Contact BFA Legislation to discuss your rights
Investors dangle till August 10, 2026, to are looking ahead to the Court to be appointed to handbook the case. The complaint asserts securities fraud claims below Sections 10(b) and 20(a) of the Securities Replace Act of 1934 on behalf of merchants in ADMA securities. The class action is pending in the U.S. District Court for the District of Current Jersey. It’s a long way captioned Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-6918.
Why is ADMA Biologics Being Sued for Securities Fraud?
ADMA has been sued for securities fraud following important stock drops which means of doable violations of the federal securities felony pointers. The decline in AMDA’s stock mark ended in important losses to merchants.
ADMA is an pause-to-pause commercial biopharmaceutical firm centered on manufacturing, marketing and constructing enviornment of abilities biologics. ADMA’s flagship product is ASCENIV, a liquid immune globulin resolution worn to treat Major Humoral Immunodeficiency in adults and kids.
In the midst of the associated length, as alleged, ADMA changed into as soon as engaged in a de facto channel stuffing diagram to drive revenue growth in the face of waning put a question to for its flagship product, ASCENIV, and didn’t repeat associated celebration transactions.
Why did ADMA Biologics’ Stock Topple?
On March 24, 2026, Culper Analysis, an investigative analysis firm, printed a document titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Linked Celebration Distributor, and –3% Real Express in 2025 vs. +20% Reported.” The document published, among other things, that in 2025 ADMA ended in one among its distributors to “stock extra ASCENIV by providing rebates and prolonged price terms in lisp to meet lisp expectations.” This allegedly allowed ADMA to e book revenue and “document[] growth that changed into as soon as never there.” Per Culper Analysis, had ADMA now not engaged in this alleged channel stuffing diagram, it would dangle skilled revenue declines of three% in 2025 moderately than the reported 20% growth.
This news ended in the rate of ADMA stock to claim no $2.26 per fragment, or 16.6%, from a closing mark of $13.59 per fragment on March 23, 2026, to $11.33 per fragment on March 24, 2026. ADMA’s stock declined a extra $1.70 per fragment, or 15%, the next day, to shut at $9.63 per fragment on March 25, 2026.
Then, on March 26, 2026, Investing.com printed an article titled “Cantor downgrades ADMA Biologics stock ranking on rapid document concerns.” This news ended in the rate of ADMA stock to claim no $1.34 per fragment, or 13.9%, from a closing mark of $9.63 per fragment on March 25, 2026, to $8.29 per fragment on March 29, 2026.
Click on right here for extra files: https://www.bfalaw.com/circumstances/adma-biologics-class-action-lawsuit.
What Can You Assemble?
Whereas you invested in ADMA Biologics, you should well moreover simply dangle apt alternate choices and are impressed to submit your files to the firm.
All illustration is on a contingency price foundation; there could be not the kind of thing as a price to you. Shareholders are now not guilty for any court docket costs or costs of litigation. The firm will glimpse court docket approval for any doable costs and costs.
Post your files by visiting:
https://www.bfalaw.com/circumstances/adma-biologics-class-action-lawsuit
Or contact:
Adam McCall
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a main global law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a high plaintiff law firm by Chambers USA, The Ethical 500, and ISS SCAS, and its attorneys had been named “Elite Trial Lawyers” by the National Legislation Journal, “Litigation Stars” by Benchmark Litigation, among the pinnacle “500 Main Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
Most recently, The Ethical 500 awarded BFA essentially the most consumer pride accolades of any plaintiff’s securities litigation law firm, with purchasers noting: “[t]right here isn’t any higher carrier provider in the notice set apart,” “[t]he hobby of the consumer is continuously entrance and center,” and “[t]right here isn’t a higher firm in this dwelling.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focal point on including mark for purchasers.”
Among its most up-to-date valuable successes, BFA recovered over $900 million in mark from Tesla, Inc.’s Board of Administrators, to boot to $420 million from Teva Pharmaceutical Ind. Ltd.
For extra files about BFA and its attorneys, please test with https://www.bfalaw.com.
https://www.bfalaw.com/circumstances/adma-biologics-class-action-lawsuit
Licensed official advertising and marketing. Past outcomes model now not narrate future outcomes.
